Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Huland

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Anticancer Research|February 24, 2001
Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumpsS Hautmann, E Huland, A Wullbrand, et al.
Anticancer Research|August 6, 2000
Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancerS Hautmann, E Huland, C Grupp, et al.
Urology|March 1, 1997
Use of serum concentration techniques to enhance early detection of recurrent prostate cancer after radical prostatectomyR S Pruthi, A Haese, E Huland, et al.
The Journal of Urology|March 1, 1997
Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladderE Lee, H Schwaibold, Y Fradet, et al.
Der Urologe. Ausg. A|July 23, 2002
[Immunotherapy of metastatic renal cell carcinoma in Germany. An assessment of the current status]E Huland, H Heinzer, S Timm, et al.
Der Urologe. Ausg. A|September 25, 2003
[Serum markers for early detection and staging of prostate cancer. Status report on current and future markers]A Haese, M Graefen, J Palisaar, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladderH Schwaibold, E Huland, H Heinzer, et al.
The Journal of Urology|April 1, 1987
Monoclonal antibody 486 P 3/12: a valuable bladder carcinoma marker for immunocytologyH Huland, R Arndt, E Huland, et al.
Urologia Internationalis|January 1, 1988
Treatment of acute cellular rejection in renal transplantation patients on ciclosporin with antithymocyte globulinR Arndt, P Hammerer, E Huland, et al.
Biochimica Et Biophysica Acta|March 21, 1985
Kinetic studies of D-glucose transport in renal brush-border membrane vesicles of streptozotocin-induced diabetic ratsM E Blank, F Bode, E Huland, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Anticancer Research|February 24, 2001
Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumpsS Hautmann, E Huland, A Wullbrand, et al.
Anticancer Research|August 6, 2000
Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancerS Hautmann, E Huland, C Grupp, et al.
Urology|March 1, 1997
Use of serum concentration techniques to enhance early detection of recurrent prostate cancer after radical prostatectomyR S Pruthi, A Haese, E Huland, et al.
The Journal of Urology|March 1, 1997
Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladderE Lee, H Schwaibold, Y Fradet, et al.
Der Urologe. Ausg. A|July 23, 2002
[Immunotherapy of metastatic renal cell carcinoma in Germany. An assessment of the current status]E Huland, H Heinzer, S Timm, et al.
Der Urologe. Ausg. A|September 25, 2003
[Serum markers for early detection and staging of prostate cancer. Status report on current and future markers]A Haese, M Graefen, J Palisaar, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladderH Schwaibold, E Huland, H Heinzer, et al.
The Journal of Urology|April 1, 1987
Monoclonal antibody 486 P 3/12: a valuable bladder carcinoma marker for immunocytologyH Huland, R Arndt, E Huland, et al.
Urologia Internationalis|January 1, 1988
Treatment of acute cellular rejection in renal transplantation patients on ciclosporin with antithymocyte globulinR Arndt, P Hammerer, E Huland, et al.
Biochimica Et Biophysica Acta|March 21, 1985
Kinetic studies of D-glucose transport in renal brush-border membrane vesicles of streptozotocin-induced diabetic ratsM E Blank, F Bode, E Huland, et al.
Pageof 6